Benjamin Derman
University of Chicago
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Benjamin Derman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:29 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05789303 · Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaUniversity of Chicago · recruiting · Multiple Myeloma, Relapse Multiple Myeloma · principal investigator
- N/ANCT04108624 · Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma PatientsUniversity of Chicago · active not recruiting · Multiple Myeloma · principal investigator
- Ph2NCT03500445 · Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple MyelomaUniversity of Chicago · active not recruiting · Myeloma, Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Integrating liquid biopsy-based epigenetic and imaging modalities to evaluate disease response in multiple myelomaR01CA280637 · NCI · UNIVERSITY OF CHICAGO · fiscal years 2023 to 2026 · $643,069 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:29 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- 72 citationsRCR 6.1
- Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.Blood · 202065 citationsRCR 2.8
- 55 citationsRCR 3.1
- 35 citationsRCR 2.4
- 35 citationsRCR 4.9
- Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.Blood Cancer J · 202419 citationsRCR 2.0
- Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.J Immunother Cancer · 202018 citationsRCR 0.7
- 17 citationsRCR 3.3
- Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.Blood Adv · 202311 citationsRCR 0.8
- A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.Eur J Haematol · 20239 citationsRCR 0.7